Guus A.M.S. van Dongen

11.6k total citations
184 papers, 8.6k citations indexed

About

Guus A.M.S. van Dongen is a scholar working on Radiology, Nuclear Medicine and Imaging, Oncology and Molecular Biology. According to data from OpenAlex, Guus A.M.S. van Dongen has authored 184 papers receiving a total of 8.6k indexed citations (citations by other indexed papers that have themselves been cited), including 132 papers in Radiology, Nuclear Medicine and Imaging, 71 papers in Oncology and 47 papers in Molecular Biology. Recurrent topics in Guus A.M.S. van Dongen's work include Radiopharmaceutical Chemistry and Applications (99 papers), Monoclonal and Polyclonal Antibodies Research (65 papers) and Medical Imaging Techniques and Applications (54 papers). Guus A.M.S. van Dongen is often cited by papers focused on Radiopharmaceutical Chemistry and Applications (99 papers), Monoclonal and Polyclonal Antibodies Research (65 papers) and Medical Imaging Techniques and Applications (54 papers). Guus A.M.S. van Dongen collaborates with scholars based in Netherlands, United States and Germany. Guus A.M.S. van Dongen's co-authors include Gerard W.M. Visser, Gordon B. Snow, Maria J.W.D. Vosjan, Lars R. Perk, Daniëlle J. Vugts, Marijke Stigter‐van Walsum, C. René Leemans, Ronald Boellaard, Marianne Budde and Elisabeth G.E. de Vries and has published in prestigious journals such as Advanced Materials, Journal of Biological Chemistry and Angewandte Chemie International Edition.

In The Last Decade

Guus A.M.S. van Dongen

182 papers receiving 8.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Guus A.M.S. van Dongen Netherlands 53 5.0k 2.9k 2.4k 2.0k 947 184 8.6k
Michael R. Zalutsky United States 62 8.3k 1.7× 3.3k 1.1× 3.1k 1.3× 2.6k 1.3× 1.1k 1.2× 360 13.4k
Robert M. Sharkey United States 57 8.0k 1.6× 5.4k 1.8× 2.9k 1.2× 2.2k 1.1× 445 0.5× 281 12.1k
Edward E. Graves United States 45 3.2k 0.6× 1.3k 0.4× 1.6k 0.7× 1.9k 0.9× 1.5k 1.6× 174 7.2k
Markus Essler Germany 50 3.5k 0.7× 1.8k 0.6× 1.8k 0.8× 3.0k 1.5× 561 0.6× 219 7.6k
Vladimir Tolmachev Sweden 56 9.4k 1.9× 4.9k 1.7× 4.0k 1.7× 1.4k 0.7× 615 0.6× 401 11.9k
Roland Haubner Germany 45 3.8k 0.8× 2.0k 0.7× 2.7k 1.1× 694 0.3× 628 0.7× 93 7.3k
Peter Smith‐Jones United States 41 3.1k 0.6× 1.9k 0.6× 2.5k 1.1× 2.9k 1.4× 444 0.5× 86 7.3k
George Sgouros United States 56 8.1k 1.6× 2.0k 0.7× 1.1k 0.5× 3.8k 1.9× 654 0.7× 194 10.2k
Kurt R. Zinn United States 45 1.6k 0.3× 1.6k 0.6× 2.6k 1.1× 1.1k 0.5× 1.5k 1.6× 203 7.1k
Sridhar Nimmagadda United States 38 1.8k 0.4× 2.1k 0.7× 1.2k 0.5× 1.3k 0.6× 619 0.7× 140 5.1k

Countries citing papers authored by Guus A.M.S. van Dongen

Since Specialization
Citations

This map shows the geographic impact of Guus A.M.S. van Dongen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Guus A.M.S. van Dongen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Guus A.M.S. van Dongen more than expected).

Fields of papers citing papers by Guus A.M.S. van Dongen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Guus A.M.S. van Dongen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Guus A.M.S. van Dongen. The network helps show where Guus A.M.S. van Dongen may publish in the future.

Co-authorship network of co-authors of Guus A.M.S. van Dongen

This figure shows the co-authorship network connecting the top 25 collaborators of Guus A.M.S. van Dongen. A scholar is included among the top collaborators of Guus A.M.S. van Dongen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Guus A.M.S. van Dongen. Guus A.M.S. van Dongen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Beaino, Wissam, Daniëlle J. Vugts, Guus A.M.S. van Dongen, et al.. (2025). Drug delivery strategies to cross the blood-brain barrier in Alzheimer’s disease: a comprehensive review on three promising strategies. The Journal of Prevention of Alzheimer s Disease. 12(7). 100204–100204. 3 indexed citations
2.
3.
4.
Merkul, Eugen, et al.. (2020). An Efficient Conjugation Approach for Coupling Drugs to Native Antibodies via the PtIILinkerLxfor Improved Manufacturability of Antibody–Drug Conjugates. Angewandte Chemie International Edition. 60(6). 3008–3015. 15 indexed citations
5.
6.
Elias, Sjoerd G., Suzanne C. van Es, Eline Boon, et al.. (2019). [89Zr]Zr-cetuximab PET/CT as biomarker for cetuximab monotherapy in patients with RAS wild-type advanced colorectal cancer. European Journal of Nuclear Medicine and Molecular Imaging. 47(4). 849–859. 19 indexed citations
7.
Thorneloe, Kevin S., Armin Sepp, Sean X. Zhang, et al.. (2019). The biodistribution and clearance of AlbudAb, a novel biopharmaceutical medicine platform, assessed via PET imaging in humans. EJNMMI Research. 9(1). 45–45. 16 indexed citations
8.
Merkul, Eugen, et al.. (2019). First platinum(II)-based metal-organic linker technology (Lx®) for a plug-and-play development of antibody-drug conjugates (ADCs). Expert Opinion on Drug Delivery. 16(8). 783–793. 16 indexed citations
9.
Merkul, Eugen, Marije Bolijn, Verónica Montserrat, et al.. (2016). A Novel Platinum(II)–Based Bifunctional ADC Linker Benchmarked Using 89Zr-Desferal and Auristatin F–Conjugated Trastuzumab. Cancer Research. 77(2). 257–267. 34 indexed citations
10.
Bahce, Idris, Marc C. Huisman, Eline E. Verwer, et al.. (2014). Pilot study of 89Zr-bevacizumab positron emission tomography in patients with advanced non-small cell lung cancer. EJNMMI Research. 4(1). 35–35. 44 indexed citations
11.
Stillebroer, Alexander B., Gerben M. Franssen, Peter F.A. Mulders, et al.. (2013). ImmunoPET Imaging of Renal Cell Carcinoma with 124 I- and 89 Zr-Labeled Anti-CAIX Monoclonal Antibody cG250 in Mice. Cancer Biotherapy and Radiopharmaceuticals. 28(7). 510–515. 42 indexed citations
12.
Vosjan, Maria J.W.D., Jo Vercammen, Joost A. Kolkman, et al.. (2012). Nanobodies Targeting the Hepatocyte Growth Factor: Potential New Drugs for Molecular Cancer Therapy. Molecular Cancer Therapeutics. 11(4). 1017–1025. 115 indexed citations
13.
Dongen, Guus A.M.S. van & Maria J.W.D. Vosjan. (2010). Immuno-Positron Emission Tomography: Shedding Light on Clinical Antibody Therapy. Cancer Biotherapy and Radiopharmaceuticals. 25(4). 375–385. 74 indexed citations
14.
Maussang, David, Ellen Langemeijer, Carlos P. Fitzsimons, et al.. (2009). The Human Cytomegalovirus–Encoded Chemokine Receptor US28 Promotes Angiogenesis and Tumor Formation via Cyclooxygenase-2. Cancer Research. 69(7). 2861–2869. 128 indexed citations
15.
Dijkers, Eli, Jos G. W. Kosterink, Lars R. Perk, et al.. (2009). Development and Characterization of Clinical-Grade 89Zr-Trastuzumab for HER2/neu ImmunoPET Imaging. Journal of Nuclear Medicine. 50(6). 974–981. 271 indexed citations
16.
Perk, Lars R., Maria J.W.D. Vosjan, Gerard W.M. Visser, et al.. (2009). p-Isothiocyanatobenzyl-desferrioxamine: a new bifunctional chelate for facile radiolabeling of monoclonal antibodies with zirconium-89 for immuno-PET imaging. European Journal of Nuclear Medicine and Molecular Imaging. 37(2). 250–259. 175 indexed citations
17.
Brouwers, Adrienne H., Iris Verel, Gerard W.M. Visser, et al.. (2004). PET Radioimmunoscintigraphy of Renal Cell Cancer Using 89 Zr-Labeled cG250 Monoclonal Antibody in Nude Rats. Cancer Biotherapy and Radiopharmaceuticals. 19(2). 155–163. 49 indexed citations
18.
Gerretsen, Martijn, Jasper J. Quak, Ruud H. Brakenhoff, Gordon B. Snow, & Guus A.M.S. van Dongen. (1994). The feasibility of radioimmunotherapy of head and neck cancer. European Journal of Cancer Part B Oral Oncology. 30(2). 82–87. 4 indexed citations
19.
Dongen, Guus A.M.S. van, et al.. (1991). Preclinical in vivo activity of 2',2'-difluorodeoxycytidine (Gemcitabine) against human head and neck cancer.. Data Archiving and Networked Services (DANS). 51(1). 211–4. 126 indexed citations
20.
Dongen, Guus A.M.S. van, Louis van de Zande, D. H. J. Schamhart, & Roeland Van Wijk. (1984). Comparative Studies on the Heat-induced Thermotolerance of Protein Synthesis and Cell Division in Synchronized Mouse Neuroblastoma Cells. International Journal of Radiation Biology and Related Studies in Physics Chemistry and Medicine. 46(6). 759–769. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Michael R. Zalutsky Breakdown of academic impact, for papers by Robert M. Sharkey Breakdown of academic impact, for papers by Edward E. Graves Breakdown of academic impact, for papers by Markus Essler Breakdown of academic impact, for papers by Vladimir Tolmachev Breakdown of academic impact, for papers by Roland Haubner Breakdown of academic impact, for papers by Peter Smith‐Jones Breakdown of academic impact, for papers by George Sgouros Breakdown of academic impact, for papers by Kurt R. Zinn Breakdown of academic impact, for papers by Sridhar Nimmagadda
Rankless by CCL
2026